Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22536823 | 1.00 | SLC2A1 (0.34) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL22536765 | 0.94 | NCEH1 (0.36) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL29879820 | 0.90 | ACHE (0.32) | SLC2A1NCEH1 | |
| SCHEMBL22536817 | 0.88 | NCEH1 (0.34) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL29880050 | 0.88 | NCEH1 (0.34) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL22536766 | 0.88 | NCEH1 (0.33) | SLC2A1NCEH1KDM4EMAPTRECQL | |
| SCHEMBL29880244 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL22536819 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL22536818 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A | |
| SCHEMBL29880441 | 0.85 | NCEH1 (0.32) | NCEH1KDM4EMAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220304972-A1 | COMBINATION THERAPY AND BIOMARKER INDICATING EFFICACY THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
| US-11414394-B2 | Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414394-B2 | Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid | ADH1A, ADH1C, DACH1 | SLC2A1 1599/4885NCEH1 1312/4885KDM4E 3573/4885 |
| US-20220304972-A1 | COMBINATION THERAPY AND BIOMARKER INDICATING EFFICACY THEREOF | MSH2, PMS2, MSH6 | SLC2A1 4459/4885NCEH1 2379/4885KDM4E 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.